| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.
|
Cancer Biol Ther
|
2011
|
1.47
|
|
2
|
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
|
Clin Cancer Res
|
2004
|
1.05
|
|
3
|
Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.
|
Mol Cancer Ther
|
2008
|
0.92
|
|
4
|
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
|
BMC Cancer
|
2011
|
0.90
|
|
5
|
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
|
Mol Cancer Res
|
2004
|
0.89
|
|
6
|
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
|
J Control Release
|
2010
|
0.87
|
|
7
|
In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.
|
Clin Cancer Res
|
2004
|
0.84
|
|
8
|
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.
|
PLoS One
|
2013
|
0.84
|
|
9
|
Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.
|
J Control Release
|
2005
|
0.83
|
|
10
|
Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.
|
Leuk Res
|
2005
|
0.82
|
|
11
|
Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
|
J Pharm Sci
|
2012
|
0.80
|
|
12
|
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
|
BMC Cancer
|
2011
|
0.79
|
|
13
|
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
|
Invest New Drugs
|
2014
|
0.78
|
|
14
|
Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.
|
J Exp Ther Oncol
|
2003
|
0.75
|